Create your own index
Analyst's views
 

15.63%

Pipeline drugs with an above average Likelihood of Approval (%) †

15.63%

Number of unique FDA approved drugs

15.63%

Breakthrough, Fast Track, and PRIME designated drugs §

15.63%

Total NAS launches

15.63%

Rare disease drug development (% of pipeline) †

15.63%

Active pipeline drug volume †

15.63%

Ongoing Phase I-IV trial activity †

15.63%

Phase I-IV trial initiations

15.63%

Partnership deal volume

15.63%

R&D Spend as % of turnover

All data for 2015 unless otherwise specified † As of 31 August 2016 § As of 1 September 2016

Create your own index

Select your value of importance

Pipeline drugs with an above average Likelihood of Approval (%) †

Number of unique FDA approved drugs

Breakthrough, Fast Track, and PRIME designated drugs §

Total NAS launches

Rare disease drug development (% of pipeline) †

Active pipeline drug volume †

Ongoing Phase I-IV trial activity †

Phase I-IV trial initiations

Partnership deal volume

R&D Spend as % of turnover